Carfilzomib is a cancer medicine that interferes with the growth and spread of cancer cells in the body. It is approved for use with lenalidomide and dexamethasone for the treatment of relapsed multiple myeloma in patients who have received one to three prior lines of therapy. Carfilzomib is injected into a vein through an IV.
SparkCures ID | 2 |
---|---|
Developed By | Amgen |
Brand Name | Kyprolis® |
Generic Name | Carfilzomib |
Additional Names | PR-171 |
Treatment Classifications | |
Tags |
|
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
The following is a listing of clinical trials for patients with Smoldering Myeloma.